DE69329252T2 - Verwendung von piperazinderivaten zur behandlung von kognitiven erkrankungen - Google Patents

Verwendung von piperazinderivaten zur behandlung von kognitiven erkrankungen

Info

Publication number
DE69329252T2
DE69329252T2 DE69329252T DE69329252T DE69329252T2 DE 69329252 T2 DE69329252 T2 DE 69329252T2 DE 69329252 T DE69329252 T DE 69329252T DE 69329252 T DE69329252 T DE 69329252T DE 69329252 T2 DE69329252 T2 DE 69329252T2
Authority
DE
Germany
Prior art keywords
pct
piperazine derivatives
treating cognitive
cognitive diseases
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69329252T
Other languages
English (en)
Other versions
DE69329252D1 (de
Inventor
Ian Anthony Cliffe
Allan Fletcher
Alan Chapman White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
John Wyeth and Brother Ltd
Original Assignee
John Wyeth and Brother Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Wyeth and Brother Ltd filed Critical John Wyeth and Brother Ltd
Publication of DE69329252D1 publication Critical patent/DE69329252D1/de
Application granted granted Critical
Publication of DE69329252T2 publication Critical patent/DE69329252T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
DE69329252T 1992-11-05 1993-10-25 Verwendung von piperazinderivaten zur behandlung von kognitiven erkrankungen Expired - Fee Related DE69329252T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929223153A GB9223153D0 (en) 1992-11-05 1992-11-05 Piperazine derivatives
PCT/GB1993/002197 WO1994009780A1 (en) 1992-11-05 1993-10-25 Use of piperazine derivatives for the treatment of cognitive disorders

Publications (2)

Publication Number Publication Date
DE69329252D1 DE69329252D1 (de) 2000-09-21
DE69329252T2 true DE69329252T2 (de) 2001-03-29

Family

ID=10724559

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329252T Expired - Fee Related DE69329252T2 (de) 1992-11-05 1993-10-25 Verwendung von piperazinderivaten zur behandlung von kognitiven erkrankungen

Country Status (18)

Country Link
US (1) US5827847A (de)
EP (1) EP0877612B1 (de)
JP (1) JP3238153B2 (de)
AT (1) ATE195422T1 (de)
AU (1) AU682155B2 (de)
CA (1) CA2148593C (de)
DE (1) DE69329252T2 (de)
DK (1) DK0877612T3 (de)
ES (1) ES2149216T3 (de)
GB (1) GB9223153D0 (de)
GR (1) GR3034400T3 (de)
HU (1) HUT72049A (de)
LV (1) LV12734B (de)
MX (1) MX9306879A (de)
PT (1) PT877612E (de)
TW (1) TW252043B (de)
WO (1) WO1994009780A1 (de)
ZA (1) ZA937827B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0710481A1 (de) * 1994-11-02 1996-05-08 Duphar International Research B.V Verwendung von Flesinoxan zur Wahrnehmungssteigerung
US6271234B1 (en) * 1997-08-01 2001-08-07 Recordati S.A., Chemical And Pharmaceutical Company 1,4-disubstituted piperazines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2355502A1 (fr) * 1976-06-23 1978-01-20 Roussel Uclaf Application a titre de medicaments d'un derive de la piperazine et de ses sels
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
GB2222768B (en) * 1988-06-17 1992-01-22 Nat Res Dev Analgesic compounds and compositions
GB8909209D0 (en) * 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives
US4902687A (en) * 1989-03-27 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
NZ233398A (en) * 1989-04-22 1991-12-23 American Home Prod Aryl- or heteroaryl-substituted piperazine derivatives and pharmaceutical compositions
ATE179973T1 (de) * 1989-04-22 1999-05-15 Wyeth John & Brother Ltd Piperazin-derivate
EP0398413A1 (de) * 1989-05-16 1990-11-22 Duphar International Research B.V 3,4-Dehydropiperidin-Derivate mit psychotroper Wirkung
DK0510068T3 (da) * 1990-01-11 1999-10-25 Upjohn Co Nye 6,7,8,9-tetrahydro-3H-benz(e)indol-heterocycler med virkning på centralnervesystemet
GB9022820D0 (en) * 1990-10-19 1990-12-05 Wyeth John & Brother Ltd Piperazine derivatives
DE4039631A1 (de) * 1990-12-12 1992-06-17 Troponwerke Gmbh & Co Kg Neuroprotektive kombination
IL101722A (en) * 1991-05-02 1996-05-14 Wyeth John & Brother Ltd History of piperazine, their preparation and pharmaceutical preparations containing them
DE4135551A1 (de) * 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen

Also Published As

Publication number Publication date
CA2148593A1 (en) 1994-05-11
JPH08502743A (ja) 1996-03-26
DE69329252D1 (de) 2000-09-21
GB9223153D0 (en) 1992-12-16
EP0877612A1 (de) 1998-11-18
ATE195422T1 (de) 2000-09-15
HUT72049A (en) 1996-03-28
GR3034400T3 (en) 2000-12-29
AU5342194A (en) 1994-05-24
AU682155B2 (en) 1997-09-25
WO1994009780A1 (en) 1994-05-11
HU9501290D0 (en) 1995-06-28
US5827847A (en) 1998-10-27
ZA937827B (en) 1995-04-21
JP3238153B2 (ja) 2001-12-10
TW252043B (de) 1995-07-21
LV12734B (en) 2002-01-20
LV12734A (en) 2001-10-20
ES2149216T3 (es) 2000-11-01
DK0877612T3 (da) 2000-10-09
MX9306879A (es) 1995-01-31
EP0877612B1 (de) 2000-08-16
CA2148593C (en) 2005-12-06
PT877612E (pt) 2000-11-30

Similar Documents

Publication Publication Date Title
DE19680619D2 (de) Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
ATE249228T1 (de) Verwendung von polyallylamin-polymeren zur herstellung eines medikamentes zur behandlung von hypercholesterolemia
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69424009T2 (de) Verwendung von (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidinacetamid zur Herstellung eines Medikaments zur Behandlung von Angst
DE69328193D1 (de) Verwendung von prodelphidinen zur behandlung von arthrose
DE69315085D1 (de) 1,4-disubstituierte piperazine zur behandlung von asthma und entzündungen der atemwege
ATE148109T1 (de) Hiv-proteaseinhibitoren und ihre verwendung zur behandlung von aids
DE59107536D1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
DE69329252D1 (de) Verwendung von piperazinderivaten zur behandlung von kognitiven erkrankungen
ATE223379T1 (de) N-aryloxyethylaminderivate zur behandlung der depression
DE69400702D1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
DE69227899D1 (de) Verwendung eines benzimidazolwurmmittels zur behandlung von mikrosporeninfektionen
ATE136217T1 (de) Verwendung von imino-derivaten von etianaldehyd zur herstellung eines arzneimittels zur behandlung des bluthochdrucks
DE69421705T2 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
DE59409813D1 (de) Imidazolochinoxalinone zur behandlung zentralnervöser erkrankungen
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
DE59309469D1 (de) Triazolochinazoline zur behandlung zentralnervöser erkrankungen
ATE145133T1 (de) Verwendung von thiol-5-(2-diethyl-aminoethyl)- ester-verbindungen zur herstellung eines arzneimittels zur behandlung der neuromuskuläre inkontinenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee